U.S. Lawmakers Question FDA on Discrepancies in Foreign Inspections of China and India
U.S. lawmakers have intensified their scrutiny of the FDA’s foreign inspection program, particularly for companies...
Novo Nordisk to Pump USD 4.1 Billion into U.S. Manufacturing Expansion
Novo Nordisk (NYSE: NVO), a Danish biopharmaceutical company, has announced plans to invest USD 4.1...
Merck KGaA’s Xevinapant Misses Primary Endpoint in Phase III Head and Neck Cancer Trial
Merck KGaA (NYSE: MRK), a leading German pharmaceutical company, has encountered a setback in the...
Suzhou Porton Biologics Becomes First Chinese CDMO to Adopt MaxCyte’s ExPERT GTx Platform
Suzhou Porton Biologics Ltd, a biopharmaceutical company based in China, has announced the introduction of...
J&J’s Tecvayli Earns NMPA Approval for Relapsed or Refractory Multiple Myeloma
Johnson & Johnson (J&J; NYSE: JNJ), a leading U.S. healthcare company, has announced that it...
Alebund Pharmaceuticals’ AP306 Earns Breakthrough Designation for Chronic Kidney Disease
Alebund Pharmaceuticals, based in Shanghai, has announced that its drug candidate AP306 (EOS789), a pan-inhibitor...
Staidson Pharmaceutical Gets FDA Clearance for TNFR2-Targeted mAb SBT-1901
Staidson (Beijing) Pharmaceutical Co., Ltd (SHE: 300204), a biopharmaceutical company based in China, has announced...
Jiangsu Jibeier Pharm Completes Private Placement to Fund R&D Center on STAR Market
Jiangsu Jibeier Pharm Co., Ltd (SHA: 688566), a Chinese pharmaceutical company, has announced the successful...
Hybio Pharmaceutical’s Biosimilar Liraglutide Gets Temporary FDA Nod Pending Patent Expiry
Hybio Pharmaceutical Co., Ltd (SHE: 300199), a Chinese pharmaceutical company, has announced that it has...
Asieris Pharmaceuticals Gets NMPA Green Light for APL-1202 Clinical Trial in FLA Infections
Asieris Pharmaceuticals (SHA: 688176), a Chinese specialist in urogenital cancer, has announced that it has...
Tonghua Dongbao Pharmaceuticals Partners with Sinopharm for Supply Chain and Market Expansion
Tonghua Dongbao Pharmaceuticals (SHA: 600867), a Chinese pharmaceutical company, has entered into a strategic partnership...
Fosun Pharma to Take Henlius Private in Deal Valued at HKD 5.407 Billion
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced plans to take...
Shanghai Haihe Pharmaceutical’s Glumetinib Earns Marketing Approval in Japan for NSCLC Treatment
Shanghai Haihe Pharmaceutical Co., Ltd, a Chinese pharmaceutical company, has announced that it has received...
Sun Yat-sen University and KingMed Diagnostics Collaborate on Talent Development and Research
On June 20, 2024, the School of Public Health (Shenzhen) of Sun Yat-sen University and...
AnDiConBio Secures Over RMB 200 Million in Series A Financing to Advance Respiratory and Pain Therapies
AnDiConBio, a Zhejiang-based innovative pharmaceutical company specializing in respiratory infections and pain management, has reportedly...
Haisco Pharmaceutical Gets NMPA Green Light for Cofrogliptin to Treat Type 2 Diabetes
Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that it has received marketing approval...
Gan & Lee Pharmaceuticals’ GZR18 Outperforms Market Similars in Weight Reduction Study
Gan & Lee Pharmaceuticals (SHA: 603087), a Chinese pharmaceutical company, has announced the presentation of...
Novo Nordisk’s Once-Weekly Insulin Awiqli Approved by China’s NMPA for Type 2 Diabetes
The National Medical Products Administration (NMPA) has granted market approval for Awiqli (insulin icodec), a...
Innovent Biologics’ Mazdutide Shows Promise in Phase III Obesity Trial
Innovent Biologics Inc. (HKG: 1801), a biopharmaceutical company based in China, has announced the presentation...
Takeda’s Fruquintinib for Metastatic Colorectal Cancer Receives European Commission Marketing Approval
HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) has announced that its partner Takeda (TYO: 4502,...